Abstract:Research and development on Nectin-4 antibody-drug conjugates (ADC) have been greatly accelerated since the approval of enfortumab vedotin to treat uroepithelial cancer. During the course of this study, we identified that autophagy serves as a cytoprotective mechanism during Nectin-4-MMAE treatment and proposed a strategy to enhance the antitumor effects of Nectin-4-MMAE in bladder cancer. Nectin-4-MMAE rapidly internalized into bladder cancer cells in 30 minutes and released MMAE, inducing the onset of caspase-mediated apoptosis and leading to the inhibition of tumor cell growth. Transcriptomics showed significant alterations in autophagy-associated genes in bladder cancer cells treated with Nectin-4-MMAE, which suggested autophagy was activated by Nectin-4-MMAE. Furthermore, autophagy activation was characterized by ultrastructural analysis of autophagosome accumulation, immunofluorescence of autophagic flux, and immunoblotting autophagy marker proteins SQSTM1 and LC3 I/II. Importantly, inhibiting autophagy by LY294002 and chloroquine significantly enhances the cytotoxicity effects of Nectin-4-MMAE in bladder cancer cells. Additionally, we detected the participation of the AKT/mTOR signaling cascade in the induction of autophagy by Nectin-4-MMAE. The combination of Nectin-4-MMAE and an autophagy inhibitor demonstrated enhanced antitumor effects in the HT1376 xenograft tumor model. After receiving a single dose of Nectin-4-MMAE, the group that received the combination treatment showed a significant decrease in tumor size compared to the group that received only one type of treatment. Notably, one mouse in the combination treatment group achieved complete remission of the tumor. The combination group exhibited a notable rise in apoptosis and necrosis, as indicated by H&E staining and immunohistochemistry (cleaved caspase-3, ki67). These findings demonstrated the cytoprotective role of autophagy during Nectin-4-MMAE treatment and highlighted the potential of combining Nectin-4-MMAE with autophagy inhibitors for bladder cancer treatment.

Nitroxoline Inhibits Bladder Cancer Progression by Reversing EMT Process and Enhancing Anti-Tumor Immunity

Nitroxoline Suppresses Metastasis in Bladder Cancer Via EGR1/circNDRG1/miR-520h/smad7/EMT Signaling Pathway.

Sodium Butyrate Inhibits Migration and Induces AMPK-mTOR Pathway-Dependent Autophagy and ROS-mediated Apoptosis Via the Mir-139-5p/bmi-1 Axis in Human Bladder Cancer Cells.

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Nitroxyl As a Potential Theranostic in the Cancer Arena.

Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer

Echinatin Inhibits Tumor Growth and Synergizes with Chemotherapeutic Agents Against Human Bladder Cancer Cells by Activating P38 and Suppressing Wnt/β-catenin Pathways

Nitidine Chloride Inhibits Renal Cancer Cell Metastasis Via Suppressing AKT Signaling Pathway.

Nitidine Chloride Inhibits Breast Cancer Cells Migration and Invasion by Suppressing C-Src/fak Associated Signaling Pathway

Effect of Inhibiting Tumor Angiogenesis on Cell Proliferation and Apoptosis in Mice With Bladder Cancer

Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle.

Biodegradable Nanoparticles Immunotherapy for the Treatment of Carcinogen-Induced Bladder Cancer

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE

Nitidine chloride regulates cell function of bladder cancer in vitro through downregulating Lymphocyte antigen 75

BRD4 Inhibitor Nitroxoline Enhances the Sensitivity of Multiple Myeloma Cells to Bortezomib in Vitro and in Vivo by Promoting Mitochondrial Pathway-Mediated Cell Apoptosis.

Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer

Successive Treatment With Naltrexone Induces Epithelial-Mesenchymal Transition And Facilitates The Malignant Biological Behaviors Of Bladder Cancer Cells

The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions

Preliminary study on inhibitory effect of matrine on bladdercancer via regulation of cyclooxygenase-2 expression in rats

Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer

Mir-381 Accelerates Apoptosis, and Inhibits Proliferation, Migration and Invasion Via PI3K/Akt Signaling Pathway by Targeting NOX4 in Non-Small Cell Lung Cancer Cells